| Autor: |
LUO, Y., HOU, W.-T., ZENG, L., LI, Z.-P., GE, W., YI, C., KANG, J.-P., LI, W. M., WANG, F., WU, D.-B., WANG, R.-Y., QU, B.- L., LI, X.- F., WANG, J.- J. |
| Zdroj: |
European Review for Medical & Pharmacological Sciences; 2020, Vol. 24 Issue 14, p7690-7697, 8p |
| Abstrakt: |
OBJECTIVE: In the era of precision medicine, molecular and genetic biomarkers act as the key indicators for glioma patients' recurrence and prognosis. MATERIALS AND METHODS: We summarize the biomarkers of glioma prognosis from molecular level, gene level and microRNA level. RESULTS: In molecular biomarkers, cyclinD1 high expression/P16 low expression, MIF high expression and VEGF high expression were all related to glioma patients' poor prognosis; in genetic biomarkers, MGMT promoter methylation absence, IDH1 wild type, HIF-a high expression, Chromosome 1p/19q non-deletion and TERT promoter mutation were associated with poor prognosis for glioma; in microRNA biomarkers, miR-524-5p, miR-586, miR-433, miR-619, miR-548d-5p, miR-525-5p, miR- 301a, miR-210, miR-10b-5p, miR-15b-5p and miRNA- 182 high expression, miR-124, miR-128, miR- 146b and miR-218 low expression were commonly seen in glioma poor prognosis patients. CONCLUSIONS: With the continuous development of science and technology, the diagnosis of glioma will tend to the gene and molecular level. Finding specific markers is helpful for the early diagnosis and accurate prognosis of glioma, which provides the possibility for individualized treatment. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
